

Remarks

Support for Amendments:

Applicants have shown some amendments in bold because text being amended is already underlined, so the added text would not otherwise be apparent.

Amendments to pages 2-3, 14, and Abstract are in response to the Notice of Allowance and the Examiner's amendment.

Amendments on page 6: There is a typographical error for Example 4 where a semi-colon is used rather than an "l". For example 5, the name of the core molecule was missed. Support is found at least in Example 1 on page 30, lines 30-31.

Support for the amendment to Example 56 on page 44 is found at least on page 45, line 5, where the trans starting material is identified. There was a typographical error in identifying the title compound 56 as "cis".

Support for the amendment to the preparation of Example 74 on page 56 is found at least on page 54, lines 24-25 (Example 72).

Support for the amendment to Example 97 (page 67) and Example 109 (page 72) is found at least in Example 40, step 4 on page 40, line 27 spanning to page 41, line 2. In each case, the reference was inadvertently made to the wrong example. It is clear from step 4 of Example 40, that Example 40 and not Example 39 should have been referenced, as Example 39 has no steps and Example 40, step 4 makes the intermediate discussed.

Claims 36 and 38 were amended to add "the (R) or (S) enantiomer thereof, or the cis or trans isomer thereof". Support is found at least on page 6, lines 31-36.

As discussed in the Notice of Allowance, a phrase had been left off of the pharmaceutical composition claim. Claim 39 had been referenced, but Applicant believes that claim 38 was intended. Applicant has amended claim 38 to add ", in combination with a pharmaceutically acceptable carrier". Claim 39 depends from claim 38, so it is believed such an amendment is not necessary for claim 39.

Claim 40 was amended to remove reference to formula I as said claim is independent and does not depend from claim 36, in which formula I is mentioned.

Claims 40 to 46 were amended to include pharmaceutically acceptable salts thereof.

Support is found at least on page 24, lines 17-27.

Claims 36 to 46 were amended to include solvates of the compound and salts thereof.

Support is found at least on page 6, lines 20-22.

New claims 47 to 51 were added. Support for the new claims is found at least on page 11, lines 20-21 and page 12, line 10 spanning to page 13, line 31.

The amendments do not add new subject matter.

Supplemental IDS

Applicants received a search report from Georgia citing the documents listed in the supplemental IDS, in addition to two references already provided and not included in the supplemental IDS (WO 00/39128 and WO 99/52907). The search report was provided by agent's cover letter dated October 2, 2006. This supplemental IDS is the required filing for the RCE.

Conclusion

Applicants believe that the amendments are supported by the application and do not add new subject matter. Applicants believe that the claims are in order for allowance, early notice of which is requested. If Examiner has any questions concerning this request, Examiner is invited to contact the below-signed attorney. As provided in the accompanying documents, please charge any required fee payment or credit any overpayment to Charge Account 16-1445.

Respectfully submitted,

/Mary J. Hosley/ _____ Date: 28 December 2006 _____
Mary J. Hosley, Attorney, Registration No. 48,324

Pfizer, Inc
150 East 42nd Street, Floor 5
New York, NY 10017-5612
Telephone No. 212.733-0460
Telefax No. 212.573-1939